Loading
Cancer, Hypoxia, and Metabolism / Nanoplatforms for Cancer Theranostics · Journal article
Advanced Science · August 11, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic preclinical report introducing two novel compounds (PDIC-AC and PDIC-NAC) designed to simultaneously inhibit glycolysis and oxidative phosphorylation in lung cancer models. PDIC-AC demonstrates superior inhibition of pyruvate dehydrogenase kinases and reactive oxygen species generation, and appears to trigger immune activation and tumor repolarization in cellular and animal systems. The work is exploratory chemistry and mechanism validation without clinical efficacy data or human translation.
Journal article. Lung cancer tumor cells and macrophages in vitro; lung cancer models (implicitly in vivo animal models).. Intervention: Two compounds: PDIC-AC (dichloroacetic acid grafted to perylenediimide via ionic bond) and PDIC-NAC (grafted via covalent bond), evaluated for dual inhibition of aerobic glycolysis and oxidative phosphorylation.. Compared with: PDIC-NAC (covalent bond variant) serves as a comparator to PDIC-AC (ionic bond variant)..
PDIC-AC exhibits significantly stronger inhibitory activity on pyruvate dehydrogenase kinases (PDHKs) than PDIC-NAC via ionic bond-driven mechanism PDIC-AC targets the Rieske iron-sulfur polypeptide 1 (UQCRFS1) subunit of complex III, triggering electron leakage and reactive oxygen species production PDIC-AC repolarizes macrophages toward anti-tumor M1 phenotype via suppression of lactate production
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is preclinical and mechanistic. No human data or clinical efficacy endpoint is presented; the findings require substantial additional validation in animal efficacy studies and eventual clinical translation before any clinical recommendation can be made.
This is a mechanistic chemistry and cell biology study demonstrating a novel compound's effects on metabolic pathways and immune cells in vitro/in vivo, without clinical efficacy data or human translation.
As stated by the source record.
This work is preclinical and mechanistic. No human data or clinical efficacy endpoint is presented; the findings require substantial additional validation in animal efficacy studies and eventual clinical translation before any clinical recommendation can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Concurrent blockade of aerobic glycolysis and oxidative phosphorylation (OXPHOS) holds great promise in lung cancer therapy yet challenged by tumor cell metabolic plasticity. To address this, we herein grafted dichloroacetic acid into perylenediimide (PDI) skeleton via ionic or covalent bond to create PDIC-AC and PDIC-NAC. Studies demonstrate that ionic bond-driven primary amine positive nitrogen remodeling and mitochondrial localization endow PDIC-AC with significantly stronger inhibitory activity on pyruvate dehydrogenase kinases (PDHKs) than PDIC-NAC. Notably, PDIC-AC targets the Rieske iron-sulfur polypeptide 1 (UQCRFS1) subunit of complex III in mitochondria, triggering electron leakage from the electron transport chain, thereby more efficiently inducing reactive oxygen species (ROS) production relative to PDIC-NAC. Superior PDHKs inhibiting efficacy and ROS generation capacity functionalize PDIC-AC as an efficient inhibitor to block glycolysis and OXPHOS, which not only repolarize macrophages toward anti-tumor M1 phenotype via suppression of lactate production, but also trigger immunogenic cell death via PERK-eIF2α-ATF4-CHOP axis to activate immune response, ultimately reaching effective chemo-immunotherapy against the primary and distant tumors. Overall, this work defines the unambiguous mechanism for PDI-triggered endogenous ROS generation, and meanwhile clarifies small-molecule regulators' energy metabolism intervention mechanism and establishes an innovative chemical bond engineering strategy for energy-targeted chemo-immunotherapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.